Danaher stock touches 52-week low at $225.36 amid market shifts

Published 29/01/2025, 18:42
Danaher stock touches 52-week low at $225.36 amid market shifts

Danaher Corporation (NYSE:DHR) stock has experienced a notable downturn, reaching a 52-week low of $225.36. With a market capitalization of $163 billion, InvestingPro analysis indicates the stock is currently trading above its Fair Value. This recent price level reflects a challenging period for the science and technology innovator, as investors recalibrate their portfolios in response to broader market trends. Trading at a P/E ratio of 42.8, the stock has attracted attention from Wall Street analysts, with consensus targets ranging from $250 to $315. Despite the company’s diverse portfolio and strong presence in the diagnostics and research sectors, maintaining an overall "GOOD" Financial Health Score, the stock has not been immune to the pressures affecting the global markets, leading to this new one-year low. Discover more comprehensive insights and 12 additional ProTips for DHR through InvestingPro’s detailed research reports.

In other recent news, Danaher Corporation experienced a series of significant developments. The company’s shares climbed following robust financial results from German life sciences company Sartorius AG (ETR:SATG), which led to positive market responses for Sartorius’s US-listed peers, including Danaher. Analysts from Barclays (LON:BARC) and JPMorgan attributed Sartorius’s strong performance to high demand for consumables, particularly for advanced therapies.

Furthermore, new export controls on biotechnology equipment announced by the U.S. Commerce Department impacted shares of various companies in the sector, including Danaher. These regulations aim to prevent the use of U.S. technology by China in military applications, potentially disrupting the sales and supply chains of affected companies.

RBC analyst Conor McNamara expressed optimism about Danaher’s future, highlighting improving visibility in the company’s end-markets and anticipating a return to historical growth levels by the second half of 2025. On another note, Guggenheim initiated coverage on Danaher shares with a Buy rating and set a price target of $275.00, underscoring Danaher’s standing as a leader in the bioprocessing industry.

Finally, Danaher Corporation projected a low-single digit percentage increase in its revenues for the fourth quarter of 2024 compared to the same period the previous year, indicating a performance that exceeds the company’s earlier expectations of a decline. These are the recent developments for Danaher Corporation.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.